CCO Treatment Updates

New Management Strategies for HCV Nonresponders and Relapsers

Module

Understanding HCV Nonresponse and Identifying Candidates for Retreatment

Faculty:
Mitchell L. Shiffman, MD

CME CREDIT INFORMATION

Release Date: 10/04/07

Expiration Date: 10/03/08

Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)™

Registered Nurses: 1.0 Nursing CE credit

Status: Please log in to view status

Mitchell L. Shiffman, MD, reviews the various types of virologic response in hepatitis C virus–infected patients treated with interferon and ribavirin-based regimens and explains how to identify patients who would be good candidates for retreatment if they fail to achieve sustained virologic response.

Learning Objectives

Upon completion of this activity, participants should be able to:

Specify standard definitions of response and nonresponse to hepatitis C virus therapy
Discuss factors associated with nonresponse to hepatitis C virus therapy
Report criteria that may help to identify nonresponders who are good candidates for retreatment
Summarize data from studies of different retreatment strategies
Describe appropriate virologic goals of therapy for nonresponders undergoing retreatment

Interactive Case Challenge

Retreatment of a Patient With Chronic HCV Infection and Previous Treatment Failure

Faculty:
Tarek Hassanein, MD

CME CREDIT INFORMATION

Release Date: 10/25/07

Expiration Date: 10/24/08

Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)™

Registered Nurses: 1.0 Nursing CE credit

Status: Please log in to view status

Tarek Hassanein, MD, reviews management strategies for optimizing future therapy success in a HCV-infected patient with previous partial treatment response on a standard interferon-based regimen.

Learning Objectives

Upon completion of this activity, participants should be able to:

Specify standard definitions of response and nonresponse to hepatitis C therapy
Discuss factors associated with nonresponse to hepatitis C therapy
Report criteria that may help to identify nonresponders who are good candidates for retreatment
Summarize data from studies of different retreatment strategies
Describe appropriate virologic goals of therapy for nonresponders undergoing retreatment

Slideset Module

New Management Strategies for HCV Nonresponders and Relapsers

Faculty:
Mitchell L. Shiffman, MD

CME CREDIT INFORMATION

Release Date: 12/05/07

Expiration Date: 12/04/08

Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)™

Registered Nurses: 1.1 Nursing CE credits

Status: Please log in to view status

Mitchell L. Shiffman, MD, reviews the various types of virologic response in patients treated for hepatitis C virus infection, discusses what factors are associated with better responses, and summarizes the most recent data available on various retreatment strategies.

Learning Objectives

Upon completion of this activity, participants should be able to:

Specify standard definitions of response and nonresponse to hepatitis C virus therapy
Discuss factors associated with nonresponse to hepatitis C virus therapy
Report criteria that may help to identify nonresponders who are good candidates for retreatment
Summarize data from studies of different retreatment strategies
Describe appropriate virologic goals of therapy for nonresponders undergoing retreatment

New Management Strategies for HCV Nonresponders and Relapsers

Format: Microsoft PowerPoint (.ppt) | File size: 1,079 KB

On-Demand Teleconference

Download Audio from Teleconference

Faculty:
Mitchell L. Shiffman, MD

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.